On March 18, 2024, Protara Therapeutics, Inc. announced that Jathin Bandari, M.D., Chief Medical Officer of the Company, will be resigning from the Company to explore other opportunities, including devoting more time to academic work, effective as of April 11, 2024. Dr. Bandari will provide consulting services to the Company through July 11, 2024. The Company expects to conduct a search to fill the Chief Medical Officer role.

In the meantime, Jacqueline Zummo, Ph.D., MPH, MBA, the Company?s Senior Vice President and Chief Scientific Operations Officer, will oversee medical staff responsible for the Company?s clinical trials, in consultation with Richard Levy, M.D., a member of the Company?s Board of Directors and the chair of the Scientific Advisory Committee of the Board.